Our results imply that BIG3 overexpression is one of the important mechanisms causing the activation of the estrogen/ERα signaling pathway in the hormone-related growth of breast cancer cells.
Introduction
Breast cancer is the most common cancer among women worldwide;
1.15-million new cases and 410,000 deaths caused by breast cancer in 2002 (Parkin et al., 2005) . Incidence of breast cancer is increasing in most countries and the increasing rate is much higher in countries where its incidence was previously low (Parkin et al., 2005) . It has been known that breast cancer is a hormone-dependent disease, and estrogens through an interaction with estrogen receptor (ER) drastically enhance the proliferative and metastatic activity in breast tumor cells (Berry et al.,2005; Yager, et al., 2006) . However, despite the clinical benefit of interruption of the ER function with synthetic anti-estrogen drugs such as tamoxifen, the precise mechanism of an estrogen/ER signaling pathway in breast cancer progression is not well understood. Therefore, further characterization of the pathophysiologic roles of this pathway and development of novel drugs targeting this pathway should be eagerly expected to provide a better management to breast cancer patients.
Gene-expression profile analysis can generate a considerable amount of information for characterizing the nature of individual cancers; such information should be applied for extraction of potential molecular targets for improving clinical strategies to treat neoplastic diseases (Bange et al., 2001; Petricoin et al., 2002) . Through the genome-wide expression analysis of a large number of microdissected clinical cancer materials we have identified dozens of genes that function as oncogenes in the process of development and/or progression of breast cancer (Park et al., 2006; Shimo et al., 2007; Lin et al., 2007; Shimo et al., 2008; Ueki et al., 2008) , bladder cancer (Kanehira et al., 2007a; 1 Kanehira et al., 2007b) , synovial sarcomas (Nagayama et al., 2004; Nagayama et al., 2005) , testicular seminoma (Okada et al., 2004) and renal cell carcinoma (Togashi et al., 2005; Hirota et al., 2006; Dobashi et al., 2009) . These molecules are considered to be good candidates for development of new therapeutic modalities.
Since cytotoxic anti-cancer drugs often cause severe adverse reactions, it is obvious that careful selection of novel target molecules on the basis of well-characterized mechanisms of action should be very helpful to develop effective anti-cancer drugs with the minimum risk of adverse events. Toward such goals, we performed expression profile analysis of 81 breast tumors and 29 normal human tissues by means of a cDNA microarray representing 23,040 cDNAs or ESTs (Nishidate et al., 2004; Saito-Hisaminato et al., 2002) and identified dozens of molecules that were over-expressed in a great majority of breast cancers and low or undetectably expressed in normal human organs.
Among many over-expressed genes in breast cancers, we report in this study identification and characterization of a novel gene, Brefeldin A-inhibited guanine nucleotide-exchange protein 3 (BIG3), a novel member of the BIG1/Sec7p subfamily of ADP ribosylation factor-GTP exchange factors (ARF-GEFs), to be a key molecule regulating an estrogen/estrogen receptor (ER) signaling pathway in breast cancer. We also demonstrate an interaction of BIG3 with prohibitin 2/repressor of estrogen receptor activity (PHB2/REA) protein, and that their interaction can enhance the ERα transcriptional activity.
Our findings imply BIG3 to be a promising target for development of novel anti-cancer drugs for breast cancer.
Results

Overexpression of BIG3 in breast cancer cells
To elucidate the mechanism of breast carcinogenesis and identify molecules that could be applicable as targets for development of novel therapeutic drugs, we previously performed genome-wide gene-expression profile analysis of 81 breast cancers using cDNA microarray representing 23,040 cDNAs (Nishidate et al., 2004) . Among the transactivated genes, we in this study focused on Brefeldin A-inhibited guanine nucleotide-exchange protein 3 (BIG3). We confirmed its upregulation in 9 of 12 clinical breast cancer specimens, compared with normal breast ductal cells or with whole mammary gland by semiquantitative RT-PCR (Figure 1a ). Subsequent northern-blot analysis confirmed overexpression of its 15-kb transcript in breast cancer cell lines (Supplementary Figure 1) . On the other hand, BIG3 expression was hardly detectable in any of normal human organs except the brain (data not shown) as concordant to the results of cDNA microarray analysis.
Since the assembled cDNA sequence of BIG3 (LOC202451; 3348bp) in the NCBI database was much smaller than the 15-kb transcript indicated by northern-blot analysis, we performed the exon-connection and 5' RACE experiments, and obtained the full-length cDNA sequences of BIG3 consisting of 14,763 nucleotides (Genebank accession; AB252196) encoding a protein of 2,177 amino acids. The BIG3 gene consists of 34 exons, spanning an approximately 183-kb genomic region on the chromosomal band 6q23.3. The simple modular architecture research tool (SMART) program predicted a presence of a Sec7 domain (586-798 amino-acids), that might be required for the protein transport through the Golgi apparatus, in the BIG3 protein (Chardin et al., 1996; Jackson et al., 2000; Cox et al., 2004; Casanova et al., 2007) .
To investigate the biological function of the BIG3 protein, we first generated an anti-BIG3 polyclonal antibody and found it to recognize the 
Effect of BIG3 on cell growth
To ascertain a possible role of BIG3 in mammary carcinogenesis, we knocked down the expression of endogenous BIG3 in breast cancer cell lines, SK-BR-3 and BT-474, which expressed a high-level of BIG3, using a mammalian vector-based RNA interference technique. Introduction of either of two BIG3-specific siRNA constructs (si-#2 and si-#3) significantly suppressed the BIG3 mRNA expression, compared with a control siRNA construct, si-mock or si-#1 (Figure 2a, b ; left panels). In concordance with the knockdown effect, MTT (Figure 2a, b ; middle panels) and colony formation assays ( Figure. 2a, b; right panels) revealed significant growth-suppressive effects by si#2 and si#3, but not significant by si#1 (mean absorbance of MTT assays in SK-BR-3 cells transfected with siBIG3 (si#1, si#2 and si#3) versus si-mock: si#1 versus si-mock, mean = 1.90 versus 2.39, difference = -0.49, 95% CI = -0.98 to -0.009, P = 0.053; si#2 versus si-mock, mean = 0.48 versus 2.39, difference = -1.90, 95% CI = -2.44 to -1.37, P = 0.003; si#3 versus si-mock, mean = 0.94 versus 2.39, difference= -1.44, 95% CI = -1.95 to -0.93, P = 0.005; mean absorbance of MTT assays in BT-474 cells transfected with siBIG3 (si#1, si#2 and si#3) versus si-mock: si#1 versus si-mock, mean = 2.23 versus 2.41, difference = -0.18, 95% CI = -0.72 to -0.36, P = 0.30; si#2 versus si-mock, mean = 0.34 versus 2.41, difference= -2.07, 95% CI = -2.63 to -1.51, P = 0.004; si#3 versus si-mock, mean = 0.43 versus 2.41, difference= -1.98, 95% CI = -2.54 to -1.42, P = 0.004). We also generated siRNA that contained a 3-base substitution in si#3 sequence (Montano, et al., 1999) (Montano, et al., 1999; Delage-Mourroux et al., 2000; Kasashima et al., 2006) , we investigated a possibility of a direct interaction between BIG3 and ERα, but failed to indicate their interaction (data not shown).
Inhibition of nuclear translocation of PHB2/REA by BIG3
Since PHB2/REA was shown to be localized mainly at cytoplasm and be translocated to the nucleus in ERα-positive cells (Montano, et al., 1999; Delage-Mourroux et al., 2000; Kasashima et al., 2006) , we hypothesized that BIG3 might interact with PHB2/REA and interfere its nuclear translocation.
Therefore, we performed immunocytochemical staining to examine the subcellular distribution of PHB2/REA protein in a presence or an absence of BIG3. Figure 4a showed that endogenous PHB2/REA was also localized in 
Discussion
Identification and characterization of cancer-related genes and their products have contributed to the development of molecular-targeting drugs for cancer therapy in the last two decades. However, the proportion of patients having benefit by presently available treatments is still limited (Berry et al.,2005; Yager, et al., 2006) . Hence, it is urgent to further develop new anticancer agents that are highly specific to malignant cells, with minimal or no adverse Little is unknown about the roles of class-II Arf (Jackson et al., 2000; Cox et al., 2004; Casanova et al., 2007) . All of Arf-GEFs identified to date are characterized by a central catalytic domain of approximately 200 amino acids referred to as the Sec7 domain that is sufficient for GEF activity (Jones et al., 1999; Jackson et al., 2000; Cox et al., 2004; Casanova et al., 2007) . Brefeldin A-inhibited guanine nucleotide-exchange proteins 1 and 2 (BIG1 and BIG2)
contain highly conserved sec7 domains that catalyze replacement of ARF-bound GDP by GTP to initiate membrane vesicle formation (Cox et al., 2004; Casanova et al., 2007) . Although it was considered to belong to the sec7/Arfs protein family, BIG3 contains a single highly-conserved Sec7 domain and shares partially the only 25% identity in amino acid sequences with BIG1 and BIG2
proteins, that were initially isolated from bovine brain cytosol on the basis of their brefeldin A-sensitive activation of calss-I Arfs (Cox et al., 2004; Yamaji et al., 2000) . Therefore, to elucidate the biological significance of BIG3 in breast cancer cells, we screened a protein(s) interacting with BIG3 and identified PHB2/REA, which is known to be an estrogen receptor α (ERα)-selective coregulator (Montano, et al., 1999; Delage-Mourroux et al., 2000; Kasashima et al., 2006) , as a candidate. We demonstrated their in vivo interaction and co-localization at the cytoplasm of breast cancer cells. We further confirmed that endogenous PHB2/REA was localized in cytoplasm under the presence of Our data should contribute to a better understanding of breast carcinogenesis, and imply that BIG3 is a promising molecular target for breast cancer treatment. 
Materials and Methods
Cell lines and clinical samples
Semiquantitative reverse transcription-PCR analysis
Microdissection of breast cancer cells was performed as described previously . Total RNAs were extracted from each of microdissected breast cancer clinical samples, microdissected normal breast ductal cells and breast cancer cell lines using RNeasy Micro Kits (Qiagen, Valencia, CA), and purchased polyA (+) RNAs isolated from mammary gland, heart, lung, liver, kidney and bone marrow from Takara Clontech (Kyoto, Japan). Subsequently, T7-based amplification and reverse transcription were carried out as described previously . Three-microgram aliquots of each amplified RNA were reversely transcribed for single-stranded cDNAs using oligo (dT) [12] [13] [14] [15] [16] [17] [18] primer and Superscript II (Invitrogen, Carlsbad, CA) at 42 o C for 60 min. We prepared appropriate dilutions of each single-stranded cDNA for subsequent PCR by monitoring β2-microgloblin (β2-MG) as a quantitative internal control.
PCR amplification was performed using EX-taq polymerase (Takara) and the 
5' rapid amplification of cDNA ends (5' RACE)
5' RACE experiments were carried out using SMART RACE cDNA amplification kit (Takara Clontech) according to the manufacturer's instructions. For the amplification of the 5' part of BIG3 cDNA, a gene-specific primer (5'-GCCTCCTTCTGCAGCTTCCTCAGGATTT-3') and a universal primer mixture supplied in the kit were used. The cDNA template was synthesized from mRNA extracted and purified from MDA-MB-453 breast cancer cells, using Superscript III Reverse Transcriptase (Invitrogen). The PCR products were cloned using TA cloning kit (Invitrogen) and sequences were determined by DNA sequencing (ABI3700; PE Applied Biosystems, Foster, CA).
Construction of BIG3 Expression Vectors
To construct BIG3 expression vector, the entire coding sequence was amplified by PCR using KOD-Plus DNA polymerase (TOYOBO, Osaka, Japan). Primer sets were 5'-CGGAATTCATGGAAGAAATCCTGAGGAAGC-3' and 5'-ATAGTTTAGCGGCCGCACAATGATGTCATAGACACGG-3' (underlines indicate recognition sites of restriction enzymes). The PCR product was inserted into the EcoRI and NheI sites of pCAGGSnH3F expression vector in frame with a hemagglutinin (HA) tag at the N-terminus and a Flag-tag at the C-terminus. DNA sequences of the construct were confirmed by DNA sequencing (ABI3700; PE Applied Biosystems).
Generation of anti-BIG3 specific polyclonal antibody
Plasmids designed to express two fragments of BIG3 (codons 459-572 and 799-1200) using pET21a (+) vector in frame with a T7 tag at the N-terminus and a histidine (His) tag at the C-terminus (Novagen, Madison, WI), respectively.
The two recombinant peptides were expressed in Escherichia coli, BL21
codon-plus strain (Stratagene, La Jolla, CA), respectively, and purified using Ni-NTA resin agarose (Qiagen) according to the supplier's protocols. The purified recombinant proteins were mixed together and then used for immunization of rabbits (Medical and Biological Laboratories, Nagoya, Japan).
The immune sera were subsequently purified on antigen affinity columns using Affigel 15 gel (Bio-Rad Laboratories, Hercules, CA) according to supplier's instructions. We confirmed that this antibody could specifically recognize endogenous BIG3 protein in breast cancer cell line, SK-BR-3 cells. An affinity-purified anti-BIG3 antibody was used for western blot, immunocytochemical and immunohistochemical analyses as described below.
Western blot analysis
To 
Immunohistochemical staining
To examine the expression of BIG3 protein in breast cancer and normal tissues, 
Gene-silencing effect by small interfering RNA
We had established a vector-based RNAi (RNA interference) expression system using psiU6BX3.0 siRNA expression vector as described previously (Shimokawa et al; 2003) . 
Immunoprecipitation and mass spectrometry
To identify an interacting protein(s) with BIG3 protein, BT-549 cells were plated onto 15-cm dishes (1 x 10 7 cells/dish) and transfected with 20µg of pCAGGSnH3F-Mock (without insertion) or pCAGGSnH3F-BIG3 using 
Co-immunoprecipitation assay
For co-immunoprecipitation assay, plasmids designed to express the entire coding sequence of PHB2/REA were constructed using the following primer set; Immunocytochemical staining was performed using anti-Flag rabbit polyclonal antibody (Sigma-Aldrich) diluted at 1:500, and Alexa 594-conjugated anti-rabbit secondary antibody (Molecular Probe, Eugene, OR) diluted at 1:1000.
Estrogen responsive element (ERE) reporter gene assays
An ERE reporter gene construct and fluorescent SEAP assay kit were purchased from Clontech (Takara, Kyoto, Japan). MCF-7 cells were transfected with siRNA-oligonucleotides of BIG3 (si-BIG3) or EGFP (si-EGFP; control) using Lipofectamin RNAiMAX (Invitrogen) in phenol red-free OptiMEM (Invitrogen) medium. After 24 h of the transfection, the cells were washed with PBS (-) at three times, and were transfected with estrogen-responsive reporter gene (pERE-TA-SEAP) vector using phenol red-free OptiMEM for 12 h.
Subsequently, 1μM of E2 was treated for 48 h for SEAP assay and western blot analysis, respectively. The SEAP reporter assay was performed using SEAP assay kit (Takara, Clontech) according to the supplier's recommendations.
Statistical analysis
All experimental data are summarized as the mean value with 95% confidence intervals (CIs). All statistical analyses were performed using the two-sample t test with Welch's correction, and were two-side. Differences were considered to be statistically significant at a value of P less than 0.05. 
